Reports: Teva developing Type 1 diabetes drug
NEW YORK — Israeli drug maker Teva Pharmaceutical Industries is developing a protein that could offer a new way to treat Type 1 diabetes, according to published reports.
Type 1 diabetes is an autoimmune disorder in which the immune system attacks the pancreas’s beta cells, but the drug, DiaPep277, stops that from happening, according to Bloomberg.
French drug maker Sanofi originally developed the drug but later gave up on it. Teva, which is developing the drug with Andromeda Biotech, has conducted a phase-3 trial of 457 patients and is planning to start a second one with 450, Bloomberg reported.
Apothecary Shops distributes GlowCap in pilot program
PHOENIX — Specialty pharmacy provider The Apothecary Shops is encouraging medication adherence with a cap for pill containers that cues patients with lights and sounds, the company said.
Apothecary Shop Wholesale is distributing GlowCap, a wireless prescription bottle cap, under a partnership with manufacturer Vitality and drug maker Novartis. The cap allows patients to plug the light in and begin receiving reminders the next day. The collaboration is part of a pilot program designed for patients using Novartis’ leukemia drug Tasigna (nilotinib) and malignant stromal tumor drug Gleevec (imatinib).
"Keeping patients on their medications is a significant problem in our country," Apothecary Shops VP clinical affairs Eric Sredzinski said. "At The Apothecary Shops, we are committed to finding and using the most effective means possible to keep our patients on their medications. That strategy underscores everything we do."
WHO approves Mylan generic HIV drugs for use in developing world
PITTSBURGH — The World Health Organization has approved three generic second-line treatments for HIV made by Mylan, the drug maker said Tuesday. The drugs will be delivered to people in developing countries living with HIV and AIDS.
Subsidiary Mylan Labs won approval for atazanavir capsules in the 300-mg strength and ritonavir tablets in the 100-mg strength with tenofovir disoproxil fumarate and lamivudine tablets in the 300-mg/300-mg strength; a fixed-dose combination of atazanavir sulfate and ritonavir tablets in the 300-mg/100-mg strength; and a fixed-dose combination tablet of abacavir sulfate, lamivudine and zidovudine in the 300-mg/150-mg/300-mg strength.
Atazanavir, ritonavir, tenofovir disoproxil fumarate and lamivudine are generic versions of Bristol-Myers Squibb’s Reyataz, Abbott Labs’ Norvir, Gilead Sciences Viread and GlaxoSmithKline’s Epivir, respectively.